1. Home
  2. DDD vs ALLO Comparison

DDD vs ALLO Comparison

Compare DDD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 3D Systems Corporation

DDD

3D Systems Corporation

HOLD

Current Price

$1.78

Market Cap

285.8M

Sector

Technology

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.40

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DDD
ALLO
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
285.8M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
DDD
ALLO
Price
$1.78
$1.40
Analyst Decision
Buy
Buy
Analyst Count
2
11
Target Price
$4.75
$8.67
AVG Volume (30 Days)
3.4M
2.6M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$391,651,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.31
$100.00
P/E Ratio
$17.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.32
$0.86
52 Week High
$5.00
$3.78

Technical Indicators

Market Signals
Indicator
DDD
ALLO
Relative Strength Index (RSI) 36.88 50.25
Support Level $1.82 $1.32
Resistance Level $1.93 $1.52
Average True Range (ATR) 0.12 0.10
MACD 0.01 -0.02
Stochastic Oscillator 14.34 32.65

Price Performance

Historical Comparison
DDD
ALLO

About DDD 3D Systems Corporation

3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: